Liptinib 250mg Tablet

About

Liptinib 250mg Tablet is an orally active, dual tyrosine kinase inhibitor that specifically targets both epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) pathways. By inhibiting the intracellular phosphorylation of these receptor tyrosine kinases, Liptinib effectively blocks downstream signaling pathways crucial for cell growth, proliferation, and survival in various cancers. This mechanism makes it particularly effective in HER2-positive breast cancer, often used in combination with other antineoplastic agents to enhance efficacy and overcome resistance mechanisms. Liptinib provides a valuable treatment option for patients with advanced or metastatic HER2-positive disease, contributing to improved progression-free survival and overall clinical outcomes.

Uses

• Treatment of advanced or metastatic HER2-positive breast cancer.
• Used in combination with capecitabine for refractory breast cancer.
• Adjuvant therapy for early-stage HER2-positive breast cancer.
• Management of HER2-positive metastatic gastric cancer.

Directions For Use

Take Liptinib 250mg Tablet orally once daily, at least one hour before or one hour after a meal, as prescribed by your oncologist. Do not crush, chew, or break the tablets.

Benefits

• Targets both EGFR and HER2 pathways effectively.
• Offers a valuable option for HER2-positive breast cancer.
• Can be used in combination for enhanced efficacy.
• Provides disease control in advanced metastatic settings.
• Improves progression-free survival in eligible patients.
• Oral administration offers convenience for patients.

Side Effects

• Diarrhea
• Rash
• Nausea
• Fatigue
• Vomiting
• Stomatitis
• Palmar-plantar erythrodysesthesia (hand-foot syndrome)
• Dry skin
• Dyspepsia
• Anorexia
• Cardiac dysfunction (rare, but serious)
• Hepatotoxicity (rare)

Safety Measures

• Alcohol - Avoid or limit alcohol consumption, as it may exacerbate gastrointestinal side effects or contribute to potential liver toxicity.
• Pregnancy - Liptinib can cause fetal harm. Women of reproductive potential must use effective contraception during treatment and for at least 1 week after the last dose.
• Breastfeeding - Breastfeeding is not recommended during treatment with Liptinib and for 1 week after the last dose, due to potential serious adverse reactions in the infant.
• Liver - Monitor liver function tests regularly. Dose adjustments or interruption may be necessary in patients with hepatic impairment.
• Kidney - No dose adjustment is typically required for mild to moderate renal impairment. Use with caution in severe renal impairment.
• Lung - Monitor for new or worsening respiratory symptoms, as interstitial lung disease can occur rarely.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.